A First-in-Human Safety Trial of MTX-463
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
Key facts
- Study ID
- NCT06401213
- Run by
- Mediar Therapeutics
- People needed
- 56
- Starts
- 2024-04-15
- Expected to finish
- 2024-11-15
- Last updated by the study team
- 2025-01-17
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- ICON — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.